Obatoclax

DB12191InvestigationalSmall molecule

Obatoclax has been used in trials studying the treatment of AML, Leukemia, Myelofibrosis, Hodgkin's Lymphoma, and Mantle-Cell Lymphoma, among others.

Mechanism: Obatoclax binds anti-apoptotic Bcl-2 proteins and interferes with their ability to interact with pro-apoptotic proteins.
Curator reviewed
Formula / weight: C₂₀H₁₉N₃O · 317.392 g/mol (avg)
Code names: GX 015-070 · GX 05-070 · GX15-070

Resolves to

Compound

Structure

InChIKeyRFTSSZJZXOSICM-GRSHGNNSSA-NSMILESCOC1=CC(=N\C1=C/C1=C(C)C=C(C)N1)C1=CC2=CC=CC=C2N1

Targets

What you can answer from here — as of September 13, 2026

6Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

19Clinical trialsPhase, status and sponsor resolved per trial

40+ReferencesStructured and connected to the statements they support

Which drugs share a target with Obatoclax, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.